<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390465</url>
  </required_header>
  <id_info>
    <org_study_id>BR1010</org_study_id>
    <nct_id>NCT03390465</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Randomized, Single Dose, 6-Sequence, 3-Period, Cross-over Study to Evaluate a Drug Interaction Between Fixed-dose Combination of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Drug interaction and safety of
      Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~48hours after medication</time_frame>
    <description>Maximum Concentration of Fimasartan, Amlodipine, Hydrochlorothiazide in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCt</measure>
    <time_frame>0~48hours after medication</time_frame>
    <description>AUCt(Area under the curve from the dosing time to the last measurable concentration) of Fimasartan, Amlodipine, Hydrochlorothiazide</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Drug-Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Arm1(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm4(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm5(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm6(N=6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</intervention_name>
    <description>Fimasartan/Amlodipine combination drug, Hydrochlorothiazide</description>
    <arm_group_label>Arm1(N=6)</arm_group_label>
    <arm_group_label>Arm2(N=6)</arm_group_label>
    <arm_group_label>Arm3(N=6)</arm_group_label>
    <arm_group_label>Arm4(N=6)</arm_group_label>
    <arm_group_label>Arm5(N=6)</arm_group_label>
    <arm_group_label>Arm6(N=6)</arm_group_label>
    <other_name>FAH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy Male adults aged 19-50 years

        Exclusion Criteria:

          -  History or presence of clinically significant medical or psychiatric condition or
             disease.

          -  Hypersensitivity to ingredient of IP and other medication, food.

          -  Participation in any other study within 3months.

          -  History of whole blood donation within 2months and Apheresis 1month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun-Young Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

